1 – 50 of 72
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
- 2022
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2021
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
- 2020
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2019
-
Mark
Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels
(
- Contribution to journal › Article
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
- 2018
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
How I manage patients with inherited haemophilia A and B and factor inhibitors
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Correlation to FVIII : C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in haemophilia care : Guideline update 2016
(
- Contribution to journal › Article
-
Mark
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
- 2016
-
Mark
Future of haemophilia outcome assessment : Registries are key to optimized treatment
(
- Contribution to journal › Article
-
Mark
Aspects of prophylactic treatment of hemophilia
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
- 2015
-
Mark
Haemophilia in Sweden – Studies on mutations and clinical implications
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Interaction between VWF and FVIII in treating VWD
(
- Contribution to journal › Article
- 2014
-
Mark
Textbook of hemophilia : Care of the child with hemophilia
2014) p.145-150(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2010
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Measuring patient-reported outcomes in haemophilia clinical research
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Management of carriers and babies with haemophilia
(
- Contribution to journal › Article
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
Plasma-derived biological medicines used to promote haemostasis
(
- Contribution to journal › Scientific review
- 2007
-
Mark
Von Willebrand factor/factor VIII concentrate (Haemate(R) P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
(
- Contribution to journal › Article
-
Mark
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
MRI assessment of haemophilic arthropathy
(
- Thesis › Doctoral thesis (compilation)
- 2006
-
Mark
The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article
- 2005
-
Mark
Changing pattern of care of boys with haemophilia in western European centres
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in von Willebrand disease
(
- Contribution to journal › Article
- 2004
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
(
- Contribution to journal › Article
- 2003
-
Mark
Structural and functional studies of factor V in health and disease
2003)(
- Thesis › Doctoral thesis (compilation)
-
Mark
HEMOPHILIA A AND B WITH SPECIAL REFERENCE TO INHIBITOR DEVELOPMENT AND EXPERIMENTAL STUDIES OF FACTORS VIII AND IX
2003)(
- Thesis › Doctoral thesis (compilation)
- 2002
-
Mark
Inhibitors in the Swedish population with severe haemophilia A and B : A 20-year survey
(
- Contribution to journal › Article
-
Mark
Factor Va-factor Xa interactions: molecular sites involved in enzyme:cofactor assembly.
(
- Contribution to journal › Article
- 2001
-
Mark
A new antitumour treatment combining radiation and electric pulses
(
- Contribution to journal › Article
- 2000
-
Mark
Treatment of children with haemophilia in Europe: A survey of 20 centres in 16 countries
(
- Contribution to journal › Article
- 1999
-
Mark
Tolerance induction using the Malmo treatment model 1982-1995
(
- Contribution to journal › Article
-
Mark
Prenatal diagnosis of haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Origin of mutation in sporadic cases of haemophilia A
(
- Contribution to journal › Article
- 1998
-
Mark
Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995
(
- Contribution to journal › Article